Novo Nordisk shares fall after deal with Trump to slash obesity drug prices

Novo Nordisk shares fell up to 3% after the company and Eli Lilly agreed to significantly lower U.S. prices for their blockbuster GLP-1 weight-loss drugs, Wegovy and Zepbound, for government programs and cash payers, reducing monthly costs from $500-$1000 to $149-$350. While analysts anticipate a near-term revenue headwind for Novo Nordisk, potentially impacting global sales growth by a low single-digit percentage next year, the move is expected to boost longer-term volumes amidst increasing competition. The agreement also covers future oral weight-loss pills, with an expedited review for Novo's candidate potentially narrowing its lead over Lilly.

Analysis

Novo Nordisk (NOVOb.CO) shares experienced an initial decline of up to 3%, settling at a 1.8% drop, following an agreement with the U.S. government to significantly reduce prices for its GLP-1 weight-loss drug, Wegovy, and Eli Lilly's (LLY.N) Zepbound. Monthly prices for U.S. government programs and cash payers will now range from $149-$350, down from $500-$1000, a move that also includes a three-year tariff relief for both companies. This immediate market reaction reflects investor concern over the pricing pressure.

Analysts, including TD Cowen, anticipate these price cuts will create a near-term revenue headwind for Novo, which projects a "low single-digit" negative impact on global sales growth next year. However, the agreement is also expected to boost volumes in the medium to long term, particularly under Medicare programs, potentially offsetting initial revenue pressures and driving future growth.

The pricing decision intensifies the competitive landscape, where Novo, despite being first to market with Wegovy, faces increasing pressure from Lilly's Zepbound and compounded copycat drugs. Furthermore, the agreement extends to future oral weight-loss pills, with an expedited FDA review process for Novo's candidate potentially limiting its head-start over Lilly, as noted by Jefferies analysts, thereby increasing competitive intensity in the pipeline as well.

Key Decisions for Investors

• Monitor Novo Nordisk's financial guidance for the precise impact of price reductions on near-term global sales growth and the anticipated timeline for increased Medicare volumes.
• Evaluate the long-term volume expansion potential from lower pricing against the backdrop of heightened competition from Eli Lilly and generic alternatives.
• Closely track the regulatory approval and commercialization timelines for oral GLP-1 treatments, as the expedited review process could significantly alter the competitive landscape and market leadership.